From Morningstar: 2024-11-08 05:22:32

In Q3 2024, Glaxo Smith Kline will pay a quarterly dividend of 15p, totaling a full-year dividend of 60p on £8 billion sales. Morningstar suggests GSK’s high dividends hinder internal R&D and acquisitions. Despite this, R&D progress was positive, with specialty medicine sales up 19%, but vaccine sales dropped 15%. Stock price is below Morningstar’s estimate at £13.74.



Read more at Morningstar: Dividend Watch: GSK Still Yielding More Than 4%